136 related articles for article (PubMed ID: 38753961)
1. Risk of Stroke in Women Using Levonorgestrel-Releasing Intrauterine Device for Contraception.
Letnar G; Andersen KK; Olsen TS
Stroke; 2024 Jul; 55(7):1830-1837. PubMed ID: 38753961
[TBL] [Abstract][Full Text] [Related]
2. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties.
Luukkainen T; Toivonen J
Contraception; 1995 Nov; 52(5):269-76. PubMed ID: 8585882
[TBL] [Abstract][Full Text] [Related]
3. Hormonal intrauterine devices.
Rybo G; Andersson K; Odlind V
Ann Med; 1993 Apr; 25(2):143-7. PubMed ID: 8489751
[TBL] [Abstract][Full Text] [Related]
4. Decline in Danish use of oral tranexamic acid with increasing use of the levonorgestrel-releasing intrauterine system: a nationwide drug utilization study.
Meaidi A; Kuhr Skals R; Alexander Gerds T; Lidegaard O; Torp-Pedersen C
Contraception; 2020 May; 101(5):321-326. PubMed ID: 31935386
[TBL] [Abstract][Full Text] [Related]
5. Intrauterine devices: an effective alternative to oral hormonal contraception.
Prescrire Int; 2009 Jun; 18(101):125-30. PubMed ID: 19637436
[TBL] [Abstract][Full Text] [Related]
6. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10.
Lidegaard O; Nielsen LH; Skovlund CW; Løkkegaard E
BMJ; 2012 May; 344():e2990. PubMed ID: 22577198
[TBL] [Abstract][Full Text] [Related]
7. Acceptability of an experimental intracervical device: results of a study controlling for selection bias.
Shain RN; Ratsula K; Toivonen J; Lähteenmäki P; Luukkainen T; Holden AE; Rosenthal M
Contraception; 1989 Jan; 39(1):73-84. PubMed ID: 2491982
[TBL] [Abstract][Full Text] [Related]
8. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
Bahamondes L; Brache V; Meirik O; Ali M; Habib N; Landoulsi S;
Hum Reprod; 2015 Nov; 30(11):2527-38. PubMed ID: 26409014
[TBL] [Abstract][Full Text] [Related]
9. Free-of-charge long-acting reversible contraception: two-year discontinuation, its risk factors, and reasons.
Saloranta TH; Gyllenberg FK; But A; Gissler M; Laine MK; Heikinheimo O
Am J Obstet Gynecol; 2020 Dec; 223(6):886.e1-886.e17. PubMed ID: 32562657
[TBL] [Abstract][Full Text] [Related]
10. Comparison of metabolic and inflammatory outcomes in women who used oral contraceptives and the levonorgestrel-releasing intrauterine device in a general population.
Morin-Papunen L; Martikainen H; McCarthy MI; Franks S; Sovio U; Hartikainen AL; Ruokonen A; Leinonen M; Laitinen J; Järvelin MR; Pouta A
Am J Obstet Gynecol; 2008 Nov; 199(5):529.e1-529.e10. PubMed ID: 18533124
[TBL] [Abstract][Full Text] [Related]
11. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices.
Sivin I; Stern J; Diaz J; Diaz MM; Faundes A; el Mahgoub S; Diaz S; Pavez M; Coutinho E; Mattos CE
Contraception; 1987 Mar; 35(3):245-55. PubMed ID: 3111785
[TBL] [Abstract][Full Text] [Related]
12. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
[TBL] [Abstract][Full Text] [Related]
13. The progestin-only pills and the levonorgestrel-releasing IUD: two progestin-only contraceptives.
Chi IC
Clin Obstet Gynecol; 1995 Dec; 38(4):872-89. PubMed ID: 8616983
[TBL] [Abstract][Full Text] [Related]
14. Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2.
Visser J; Snel M; Van Vliet HA
Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD003990. PubMed ID: 23543528
[TBL] [Abstract][Full Text] [Related]
15. Complications and continuation of intrauterine device use among commercially insured teenagers.
Berenson AB; Tan A; Hirth JM; Wilkinson GS
Obstet Gynecol; 2013 May; 121(5):951-958. PubMed ID: 23635730
[TBL] [Abstract][Full Text] [Related]
16. Weight change at 12 months in users of three progestin-only contraceptive methods.
Vickery Z; Madden T; Zhao Q; Secura GM; Allsworth JE; Peipert JF
Contraception; 2013 Oct; 88(4):503-8. PubMed ID: 23582238
[TBL] [Abstract][Full Text] [Related]
17. Two years' experience with two levonorgestrel-releasing intrauterine devices and one copper-releasing intrauterine device: a randomized comparative performance study.
Nilsson CG; Allonen H; Diaz J; Luukkainen T
Fertil Steril; 1983 Feb; 39(2):187-92. PubMed ID: 6401636
[TBL] [Abstract][Full Text] [Related]
18. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study.
Luukkainen T; Allonen H; Haukkamaa M; Holma P; Pyörälä T; Terho J; Toivonen J; Batar I; Lampe L; Andersson K
Contraception; 1987 Aug; 36(2):169-79. PubMed ID: 3123132
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of the levonorgestrel-releasing IUD: its advantages and disadvantages when compared to the copper-releasing IUDs.
Chi IC
Contraception; 1991 Dec; 44(6):573-88. PubMed ID: 1773615
[TBL] [Abstract][Full Text] [Related]
20. Intracervical and fundal administration of levonorgestrel for contraception: endometrial thickness, patterns of bleeding, and persisting ovarian follicles.
Pakarinen PI; Suvisaari J; Luukkainen T; Lähteenmäki P
Fertil Steril; 1997 Jul; 68(1):59-64. PubMed ID: 9207585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
